Real World Evidence and Digital Convergence in Medical Affairs

Webcasts

Thursday, January 20, 2022 at 2pm EST A set of broad trends in technology, data science, and RWE strategy is converging to shape the future of Medical Affairs. This webinar will explore perspectives from Medical Affairs professionals on how RWE and digital convergence are influencing a variety of functions within Medical Affairs organizations.

Register Free: http://www.pharmexec.com/pe_w/digital_convergence

Event Overview:

A set of broad trends in technology, data science, and RWE strategy is converging to shape the future of Medical Affairs. These elements are influenced by a range of factors including advances in computing power, data networks, evidence requirements for precision medicine, channels for data dissemination, and evolving regulatory policy aimed at increasing the value and quality of healthcare.

This expert panel discussion will explore perspectives from Medical Affairs professionals on how RWE and digital convergence are influencing a variety of functions within Medical Affairs organizations. Examples include approaches to support RWE generation for increasingly sophisticated treatments, the rise of patient centricity, data dissemination, and external customer engagement with field medical teams.

Key Takeaways:

  • Obtain expert views on trends that underpin the transformation of the Medical Affairs function.
  • Gain an understanding of the latest methods and tools used in RWE generation.
  • Learn how Medical Affairs teams view the current digital environment to anticipate rapid changes impacting the industry.

Speakers

Tony Gottschalk
Senior Principal, Medical Affairs
Medical Affairs CoE, IQVIA

Tony has over 20 years of experience in biopharma across commercial, clinical, Medical Affairs, regulatory, and Health IT. He joined IQVIA in 2019 and specializes in supporting Medical Affairs customers in the design and execution of innovative RWE programs. Previously, Tony was Vice President, Specialty Access Programs at CoverMyMeds. At Gilead Sciences, from 2008-2017, Tony led patient support programs, REMS systems, and specialty pharmacy operations. Earlier in his career, he worked in commercial and clinical at Actelion, Cotherix, Quintiles, Roche Labs, and Abbott. Tony earned dual executive MBA degrees from Columbia Business School and Berkeley Haas, and he has a BA in Molecular, Cellular, and Developmental Biology from the University of Colorado at Boulder.

Judy Lytle, PhD, MBEE, PMP
Principal, Medical Affairs Strategy
Medical Affairs CoE, IQVIA

Judy has 15 years of experience in biomedical research, project/program management, and business development since earning her PhD, with focus on therapeutic areas including neurology and psychiatry, genetics, bioinformatics, and infectious disease. Judy leverages her expertise in biomedical research, and her experience along the R&D pipeline, to support and improve patient-centric outcomes. She has experience with first-of-its-kind and specialty therapeutics, orphan designation, and REMS programs. In her current role, Judy is responsible for guiding quality delivery of existing solutions to meet needs in Medical Affairs and innovating the next generation of medical offerings.

Prior to joining IQVIA, Judy held field-based and in-house positions in Medical Affairs in Pharma. She also has extensive experience in federal government, academic, and non-profit roles supporting biomedical research and development. Judy holds a BS in Biology from Ursinus College, a PMP from the Project Management Institute, an MBEE from Johns Hopkins University, and a PhD in Neuroscience from Georgetown University.

Cassie Holt, PhD
Health Outcomes Director
Novo Nordisk, Inc.

Dr. Cassie Holt is a Health Outcomes Director at Novo Nordisk, Inc. where she serves as the East region’s expert health economics and outcomes research (HEOR) resource, enhancing value communication for the Field Medical Affairs team. She aims to build relationships with thought leaders, population health decision makers, and data scientists, and to identify and assess opportunities for research partnerships.Dr. Holt is also experienced in global real world offering development and innovation, and managing projects utilizing real world data (e.g., electronic medical records, claims data, registries, etc.) to produce evidence and generate insights for multiple stakeholders in the pharmaceutical industry.She is an epidemiologist by training, receiving both her Ph.D. and MPH from the University of Pittsburgh where she researched type 2 diabetes prevention and the impact of psychosocial factors on key outcomes in type 1 diabetes.While offline, Dr. Holt enjoys spending time with her husband and daughter, cooking, reading, traveling, and taking Peloton and Pure Barre classes

Register Free: http://www.pharmexec.com/pe_w/digital_convergence